66 publications
| Name | Date | Type | Actions |
|---|---|---|---|
Monthly information regarding the total number of voting rights and shares making of the share capital - February 2020 As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » |
Voting rights | ||
Vetoquinol to acquire rights for Profender® and Drontal® from Elanco Animal Health for the European economic area and the UK February 12 th , 2020 (Lure, France) - Vetoquinol has agreed terms to acquire the European Economic area and UK rights to Profender® and Drontal® product families from Elanco Animal Health. |
Public releases | ||
Monthly information regarding the total number of voting rights and shares making of the share capital - January 2020 As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » |
Voting rights | ||
2019 sales: €396.0 million (Up 7.6%) The Vetoquinol Group posted 2019 sales of €396.0 million, up 7.6% as reported and up 6.1% at constant exchange rates. |
Public releases | ||
Monthly information regarding the total number of voting rights and shares making of the share capital - December 2019 |
Voting rights | ||
Vetoquinol and Klox Technologies Announce Global Animal Health Collaboration Agreement December 12, 2019 (Lure, France) - Vetoquinol S.A. and Klox Technologies Limited, a subsidiary of Klox Technologies Inc., have entered into an exclusive global licensing agreement, excluding the People’s Republic of China. |
Public releases | ||
Monthly information regarding the total number of voting rights and shares making of the share capital - November 2019 As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » |
Voting rights | ||
Monthly information regarding the total number of voting rights and shares making of the share capital - October 2019 As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » |
Voting rights | ||
Q3 2019 sales: €100.2 million (Up 11.0%) The Vetoquinol Group posted sales of €100.2 million for the third quarter of 2019, up 11.0% as reported and up 9.4% at constant exchange rates compared to the same period last year. |
Public releases | ||
Monthly information regarding the total number of voting rights and shares making of the share capital - September 2019 As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » |
Voting rights |